These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38843542)

  • 21. Elevated creatine phosphokinase and rhabdomyolysis associated with elexacaftor/tezacaftor/ivacaftor use in cystic fibrosis.
    McKinzie CJ; Kam CW; Jones MC; Gifford LB; Loughlin CE; Noah TL; Shenoy VK; Dellon EP
    Pediatr Pulmonol; 2024 Jun; 59(6):1795-1797. PubMed ID: 38517044
    [No Abstract]   [Full Text] [Related]  

  • 22. Peripheral lung effect of elexacaftor/tezacaftor/ivacaftor in adult cystic fibrosis.
    Stylemans D; Darquenne C; Schuermans D; Verbanck S; Vanderhelst E
    J Cyst Fibros; 2022 Jan; 21(1):160-163. PubMed ID: 33832855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of elexacaftor/tezacaftor/ivacaftor on liver fibrosis markers in adults with cystic fibrosis.
    Tewkesbury DH; Scott J; Barry PJ; Bright-Thomas RJ; Hanley KP; Athwal V; Jones AM
    J Cyst Fibros; 2024 Mar; 23(2):349-353. PubMed ID: 37735009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elexacaftor/tezacaftor/ivacaftor (Trikafta) for cystic fibrosis.
    Med Lett Drugs Ther; 2020 Jan; 62(1589):5-7. PubMed ID: 31999662
    [No Abstract]   [Full Text] [Related]  

  • 25. Behavioural and sleep issues after initiation of elexacaftor-tezacaftor-ivacaftor in preschool-age children with cystic fibrosis.
    Sermet-Gaudelus I; Benaboud S; Bui S; Bihouée T; Gautier S;
    Lancet; 2024 Jul; 404(10448):117-120. PubMed ID: 38950554
    [No Abstract]   [Full Text] [Related]  

  • 26. Year in review 2023 - Back to the future.
    Cristiani L; Fernandes FF
    J Cyst Fibros; 2024 Mar; 23(2):203-207. PubMed ID: 38431442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A longitudinal study assessing the impact of elexacaftor/tezacaftor/ivacaftor on gut transit and function in people with cystic fibrosis using magnetic resonance imaging (MRI).
    Yule A; Ng C; Recto A; Lockwood F; Dellschaft NS; Hoad CL; Zagoya C; Mainz JG; Major G; Barr HL; Gowland PA; Stewart I; Marciani L; Spiller RC; Smyth AR
    J Cyst Fibros; 2024 Sep; 23(5):984-990. PubMed ID: 39242338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elexacaftor/tezacaftor/ivacaftor's effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment.
    Morgan SJ; Coulter E; Betts HL; Solomon GM; Clancy JP; Rowe SM; Nichols DP; Singh PK;
    J Clin Invest; 2024 Sep; 134(20):. PubMed ID: 39235967
    [No Abstract]   [Full Text] [Related]  

  • 29. Protocol for Successful Desensitization to Ivacaftor and Elexacaftor/Tezacaftor/Ivacaftor in a Delayed Hypersensitivity Reaction Confirmed by the Lymphocyte Transformation Test.
    Mir-Ihara P; De Las Vecillas L; Heredia R; Fiandor A; González-Muñoz M; Zamarrón E; Prados C; Cabañas R
    J Investig Allergol Clin Immunol; 2024 Jun; 34(3):211-213. PubMed ID: 37966860
    [No Abstract]   [Full Text] [Related]  

  • 30. Analysis of Depression and Anxiety Scores Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Adults With Cystic Fibrosis.
    Pudukodu H; Powell MZ; Ceppe A; Donaldson SH; Goralski JL; Sowa NA
    Clin Respir J; 2024 Sep; 18(9):e70007. PubMed ID: 39210645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multisystemic Effects of Elexacaftor-Tezacaftor-Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease.
    Burgel PR; Paillasseur JL; Durieu I; Reynaud-Gaubert M; Hamidfar R; Murris-Espin M; Danner-Boucher I; Chiron R; Leroy S; Douvry B; Grenet D; Mely L; Ramel S; Montcouquiol S; Burnet E; Ouaalaya EH; Sogni P; Da Silva J; Martin C;
    Ann Am Thorac Soc; 2024 Jul; 21(7):1053-1064. PubMed ID: 38579175
    [No Abstract]   [Full Text] [Related]  

  • 32. At-home compounding preparation of slow desensitization of elexacaftor/tezacaftor/ivacaftor for delayed hypersensitivity rash.
    Muirhead C; Verzasconi D; Joshi S
    Pediatr Pulmonol; 2022 Jul; 57(7):1779-1781. PubMed ID: 35451238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eligibility of CFTR modulators for the adult-diagnosed cystic fibrosis population.
    Desai S; Lam GY; Sykes J; Stephenson AL; Quon BS
    J Cyst Fibros; 2020 Sep; 19(5):840-841. PubMed ID: 32505524
    [No Abstract]   [Full Text] [Related]  

  • 34. Mood Swings and Irritability in a Patient With Cystic Fibrosis on Elexacaftor-Tezacaftor-Ivacaftor Therapy: A Case Report.
    Lan YT; Wung YT
    J Clin Psychopharmacol; 2024 Sep-Oct 01; 44(5):528-530. PubMed ID: 39173037
    [No Abstract]   [Full Text] [Related]  

  • 35. CFTR modulator use in post lung transplant recipients.
    Benninger LA; Trillo C; Lascano J
    J Heart Lung Transplant; 2021 Dec; 40(12):1498-1501. PubMed ID: 34538541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease.
    Terlizzi V; Colangelo C; Marsicovetere G; D'Andria M; Francalanci M; Innocenti D; Masi E; Avarello A; Taccetti G; Amato F; Comegna M; Castaldo G; Salvatore D
    Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New Drug Hailed as Major Breakthrough in Cystic Fibrosis.
    Am J Med Genet A; 2020 Jan; 182(1):8-9. PubMed ID: 31825178
    [No Abstract]   [Full Text] [Related]  

  • 38. Unmasking catamenial hemoptysis in the era of CFTR modulator therapy.
    Montemayor K; Claudio AT; Carson S; Lechtzin N; Christianson MS; West NE
    J Cyst Fibros; 2020 Jul; 19(4):e25-e27. PubMed ID: 31987762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elexacaftor/Tezacaftor/Ivacaftor Improved Clinical Outcomes in a Patient with N1303K-CFTR Based on
    Huang Y; Paul G; Lee J; Yarlagadda S; McCoy K; Naren AP
    Am J Respir Crit Care Med; 2021 Nov; 204(10):1231-1235. PubMed ID: 34379998
    [No Abstract]   [Full Text] [Related]  

  • 40. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
    N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.